Effect of Sorafenib on Liver Biochemistry Prior to Vitamin B17 Coadministration in Ehrlich Ascites Carcinoma Mice Model: Preliminary Phase Study

Aim: Background: Voluminous of the anti-tumor drugs in practice known to yield adverse side effects for instance hepatotoxicity. Objective: This preliminary was carried out to ascertain the histological change after treatment with Sorafenib (SOR) before execution the B17 coadministration and detection of the histochemical change in Ascites Carcinoma mice model (EAC). Methods: In total 12 Swiss albino mice received intraperitoneal injections of Sorafenib (30 mg/ kg mouse) after tumor cells were injected, semi quantifiable scoring of the architectural disparitiesvalidated by histo-pathological inspection of mice tissues. Results: Upsurge of Liver enzymes, Kidney functions and significant reduction after SOR treatment of Hb, RBCs, and Platelets. Membrane integrity, Separation of muscle fiber, Intrusion of inflammatory cells, Edematous intramuscular space were evaluated in addition, liver tissue revealed large focal area and diffuse pleomorphic darkly basophilic cells in the perivascular area around the dilated central vein (CV) besides the mild dilation of some blood sinusoids. Improvement in the histological pictures of hepatic tissues in comparison to EAC bearing positive control group were enhanced Conclusion: Sorafenib showed alterations in histological mice tissues, however, improvements in biochemical parameters were noted; that’s why the Coadministration of B17 will be applied to alleviate the side effects of Sorafenib on the next perspective study.